Trial Profile

A Phase Ib Multi-Center, Double-Blind, Randomized, Placebo-Controlled Dose Escalation Study of the Safety, Tolerability and Immunogenicity of ACI-24 in Adults With Down Syndrome

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ACI 24 (Primary)
Indications Down syndrome
Focus Pharmacodynamics
Acronyms 3-Star
Sponsors AC Immune

Most Recent Events

09 May 2022 Results assessing safety, tolerability, and immunogenicity of the ACI-24 vaccine among adults with Down syndrome published in the JAMA Neurology
30 Jul 2021 Results presented at the Alzheimer's Association International Conference 2021
29 Jul 2021 According to an AC Immune media release, results from this study presented at Alzheimers Association International Conference

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com